Evaluating the Impact of Cell Culture Supplements on CHO Clonal Outgrowth Efficiency

Assuring that a stable cell line originates from a single progenitor cell is a fundamental component of the development of protein, cellular and gene therapies. However, assuring clonality is often a rate-limiting step in cell line development, leading to project delays and increased risk.

The generation of clonal cell lines is a fundamental component of the biomanufacturing of protein, cellular and gene therapies. However, single-cell cloning can introduce risks due to low cell viability and potential delays to cell line development workflows, particularly because single cells often fail to proliferate without adequate nutritional support.

This webinar will present insights from a long-term collaboration combining data from multiple independent single-cell cloning studies conducted in a cell line development setting. Together, these case studies show how optimized supplementation strategies can support robust early clonal outgrowth while reducing variability across different cell pools and cloning campaigns.

The featured speakers will focus on what drives reproducible single-cell outgrowth in CHO CLD platforms and how workflow choices influence both performance and consistency. Attendees will gain practical guidance on evolving single-cell cloning strategies to move beyond incremental improvements and toward more reliable, scalable and future-ready CHO cell line development workflows.

Register for this webinar to learn how cell culture supplements can support reproducible CHO clonal outgrowth and reduce variability in cell line development workflows.

Speakers

Adam Causer, Global Product Manager, Solentim Portfolio, Nova Biomedical

Adam Causer is a Global Product Manager for the Solentim Portfolio at Nova Biomedical, which includes an ecosystem of instruments that digitalize and automate CLD workflows. Prior to starting this role, he worked in Application Sciences at both Scienion and Advanced Instruments, specializing in precision dispensing and single-cell isolation for diagnostic test development and CLD, respectively.

Adam’s early career included being a Postdoctoral Researcher that oversaw the day-to-day management of Cancer Research UK (CRUK), National Institute for Health Research (NIHR) and university-funded research projects. For these projects, he used a combination of basic science and physiological techniques to investigate the benefits of exercise on health, disease and pharmaceutical treatments. These techniques included cell culture, live cell imaging, flow cytometry, cell killing assays and multiplex protein quantification.

Message Presenter

Dorothee Düsterhöft, Associated Scientist, Cell Line Development, UGA Biopharma

Dorothee Düsterhöft is an Associate Scientist in Cell Line Development at UGA Biopharma, where she develops cell lines (CHO, HEK, iPSC) for therapeutic drug candidates used in commercial manufacturing. Her work focuses on optimizing single cell cloning through systematic evaluation of cloning supplements, implementing high throughput approaches, and applying quality and regulatory principles for monoclonality assessment. She also designs data driven experiments to accelerate CLD timelines.

Prior to joining UGA Biopharma, Dorothee worked in functional genomics at the Max Planck Institute for Evolutionary Anthropology, where she improved gene editing efficiency in human stem cells using prime editing strategies. She holds an M.Sc. in Biochemistry from the University of Leipzig, and a B.Sc. in Biochemistry from the University of Greifswald.

Message Presenter